Vinorelbine News and Research

RSS
Vinorelbine is an anticancer drug that belongs to the family of plant drugs called vinca alkaloids.
Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Precision Therapeutics’ ChemoFx test feasible in cervical cancer

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

Combination therapy shows promise against HER2-positive metastatic breast cancer

Combination therapy shows promise against HER2-positive metastatic breast cancer

YM announces updates on nimotuzumab clinical development program

YM announces updates on nimotuzumab clinical development program

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

ADVENTRX submits NDA for Exelbine to FDA

ADVENTRX submits NDA for Exelbine to FDA

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

ADVENTRX announces Exelbine 12-month stability test results

ADVENTRX announces Exelbine 12-month stability test results

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online